Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neuphoria Therapeutics ( (NEUP) ) has issued an announcement.
On October 20, 2025, Neuphoria Therapeutics announced that its AFFIRM-1 Phase 3 trial for BNC210 in treating social anxiety disorder did not meet its primary or secondary endpoints. As a result, the company will discontinue its SAD program and conduct a strategic review of its operations and portfolio. Neuphoria will focus on potential developments for BNC210 in PTSD and maintain its partnership with Merck, which includes a Phase 2 trial for Alzheimer’s disease. The company reported a cash position of $14.2 million as of June 30, 2025, expected to fund operations through mid-2027.
The most recent analyst rating on (NEUP) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Neuphoria Therapeutics stock, see the NEUP Stock Forecast page.
More about Neuphoria Therapeutics
Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for neuropsychiatric disorders. Its lead drug candidate, BNC210, is an anti-anxiety therapeutic designed to provide rapid relief from stress and anxiety without sedation or addiction. Neuphoria has strategic partnerships with Merck & Co., Inc. for treatments in Alzheimer’s disease and other CNS conditions, and with Carina Biotech for oncology programs.
Average Trading Volume: 72,193
Technical Sentiment Signal: Buy
Current Market Cap: $36.59M
Learn more about NEUP stock on TipRanks’ Stock Analysis page.